Nirmatrelvir
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2023
- First approval year
- 2023
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Nirmatrelvir
- Molecular weight
- 499.53
- Structure (SMILES)
- CC(C)(C)[C@H](NC(=O)C(F)(F)F)C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@H](C#N)C[C@@H]1CCNC1=O)C2(C)C
- nirmatrelvir component of paxlovid
- Nirmatrelvir component of paxlovid
- molnupiravir and nirmatrelvir ritonavir e g paxlovid
- nirmatrelvir
- Nirmatrelvir
- nirmatrelvir [INN]
- NIRMATRELVIR [JAN]
- Nirmatrelvir [MI]
- NIRMATRELVIR [USAN]
- Nirmatrelvir [WHO-DD]
- nirmatrelvir inn
- nirmatrelvir jan
- nirmatrelvir mi
- nirmatrelvir usan
- nirmatrelvir who dd
- paxlovid component nirmatrelvir
- PAXLOVID COMPONENT NIRMATRELVIR
- pf 07321332
- Pf-07321332
- PF-07321332
- pf07321332
- PF07321332
- CAS registry numbers
- 2628280-40-8
- ChEMBL ID
- CHEMBL4802135
- InChIKey
- LIENCHBZNNMNKG-OJFNHCPVSA-N
- PubChem compound IDs
- 155903259
- RxNorm IDs (RxCUI)
- 2587892
- FDA ingredient codes (UNII)
- 7R9A5P7H32
- Applicant
- PFIZER
- Approval date
- 25 May 2023
- Application number
- NDA217188
- First in class
- Yes
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- nirmatrelvir
- Type
- Synthetic organic
- Drug name stem
- -vir
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Agonist
- Action type
- Agonist
- Target
- TAS2R1
- Gene symbol
- TAS2R1
- Protein identifier
- Q9NYW7
- Mechanism
- SARS coronavirus 3C-like proteinase inhibitor
- Action type
- Inhibitor
- Target
- Replicase polyprotein 1a
- Protein identifier
- P0C6U8
Open Targets mechanisms
- Mechanism
- SARS coronavirus 3C-like proteinase inhibitor
- Action type
- Inhibitor
- Target
- Replicase polyprotein 1a
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Pneumonia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Influenza, Human
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition
- COVID-19
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition
- Post-Acute COVID-19 Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100233
- Subject identifier
- D000094024
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- HP_0002094
- Highest recorded phase
- 2
- Condition identifier
- HP_0012378
- Highest recorded phase
- 2
- Condition identifier
- HP_0040182
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005300
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005812
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007008
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0011479
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100163
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100233
- Highest recorded phase
- 2
- Event
- acute kidney injury
- Reports
- 10
- Reporting signal score
- 31.3259
- Event
- bacterial translocation
- Reports
- 2
- Reporting signal score
- 15.4604
- Event
- drug interaction
- Reports
- 20
- Reporting signal score
- 82.2359
- Event
- immunosuppressant drug level abnormal
- Reports
- 2
- Reporting signal score
- 22.0763
- Event
- immunosuppressant drug level increased
- Reports
- 6
- Reporting signal score
- 36.643
- Event
- toxicity to various agents
- Reports
- 13
- Reporting signal score
- 48.0538
- NCT02735707
- NCT04483960
- NCT04746183
- NCT04960202
- NCT05011513
- NCT05047601
- NCT05261139
- NCT05321394
- NCT05341609
- NCT05386472
- NCT05438602
- NCT05487040
- NCT05545319
- NCT05567952
- NCT05601167
- NCT05614349
- NCT05682586
- NCT04381936
- NCT04909853
- NCT05005312
- NCT05576662
- NCT05668091
- NCT05965726
- Dose
- 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet)
- Route
- Oral
- How often
- Twice daily for 5 days
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 3
- Polar surface area
- 131.4
- Calculated partition coefficient (ALogP)
- 1.1
- Calculated partition coefficient (XLogP)
- 2.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 35
- Molecular formula
- C23H32F3N5O4
- Monoisotopic mass
- 499.24063901
- Natural product
- No
- Recorded assays
- 618
- Active assays
- 274
Active assay types
- Confirmatory
- Viral Protease Inhibitors
These details could not be displayed.
Related records
Trials (54)
- A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.
- A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
- A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
- A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection
- A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants
- A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
- A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
- A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women
- A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
- A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco
- A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
- A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
- A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
- A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.
- A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
- A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.
- A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
- A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
- A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
- A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
In development for (7)
- COVID-19 Phase 3
- Influenza Phase 3
- Kidney disorder Phase 1
- Liver disorder Phase 1
- Long COVID-19 Phase 2
- Pneumonia Phase 3
- Severe acute respiratory syndrome Phase 3